Latest Insider Transactions at Kaleido Biosciences, Inc. (KLDO)
This section provides a real-time view of insider transactions for Kaleido Biosciences, Inc. (KLDO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kaleido Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kaleido Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2022
|
Jerald Korn COO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,046
-31.17%
|
$2,046
$1.49 P/Share
|
|
Feb 28
2022
|
Vlieg Johan Van Hylckama Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,087
-31.12%
|
$2,087
$1.49 P/Share
|
|
Feb 08
2021
|
Daniel L Menichella Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$220,000
$11.5 P/Share
|
|
Feb 08
2021
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
215,000
+5.09%
|
$2,365,000
$11.5 P/Share
|
|
Jun 04
2020
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,000,000
+32.62%
|
$14,000,000
$7.5 P/Share
|
|
Mar 04
2019
|
Flagship Ventures Fund V General Partner LLC Director |
BUY
Open market or private purchase
|
Indirect |
933,333
+9.07%
|
$13,999,995
$15.0 P/Share
|
|
Mar 04
2019
|
Flagship Ventures Fund V General Partner LLC Director |
BUY
Conversion of derivative security
|
Indirect |
11,070,951
+30.95%
|
-
|
|
Mar 04
2019
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,120,697
+39.13%
|
-
|